JP2014510520A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510520A5 JP2014510520A5 JP2013554547A JP2013554547A JP2014510520A5 JP 2014510520 A5 JP2014510520 A5 JP 2014510520A5 JP 2013554547 A JP2013554547 A JP 2013554547A JP 2013554547 A JP2013554547 A JP 2013554547A JP 2014510520 A5 JP2014510520 A5 JP 2014510520A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- mouse
- human
- cell
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 53
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 52
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 47
- 241000699670 Mus sp. Species 0.000 claims description 28
- 238000010172 mouse model Methods 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 17
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 16
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 12
- 210000002540 macrophage Anatomy 0.000 claims description 12
- 210000001616 monocyte Anatomy 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 150000007523 nucleic acids Chemical group 0.000 claims description 11
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 10
- 230000000638 stimulation Effects 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 8
- 230000028327 secretion Effects 0.000 claims description 8
- 210000000952 spleen Anatomy 0.000 claims description 8
- 101100193633 Danio rerio rag2 gene Proteins 0.000 claims description 7
- 101100193635 Mus musculus Rag2 gene Proteins 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 244000052637 human pathogen Species 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 claims description 4
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 230000036765 blood level Effects 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 108700028369 Alleles Proteins 0.000 claims description 3
- 108700024394 Exon Proteins 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims description 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims description 2
- 241000186359 Mycobacterium Species 0.000 claims description 2
- 206010057249 Phagocytosis Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 230000035605 chemotaxis Effects 0.000 claims description 2
- 102000054189 human CD80 Human genes 0.000 claims description 2
- 102000049849 human CD86 Human genes 0.000 claims description 2
- 102000052611 human IL6 Human genes 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 230000008782 phagocytosis Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000003827 upregulation Effects 0.000 claims description 2
- 238000003209 gene knockout Methods 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 2
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 description 4
- 230000003915 cell function Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100026234 Cytokine receptor common subunit gamma Human genes 0.000 description 1
- 101001055227 Homo sapiens Cytokine receptor common subunit gamma Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161442946P | 2011-02-15 | 2011-02-15 | |
| US61/442,946 | 2011-02-15 | ||
| PCT/US2012/025040 WO2012112544A2 (en) | 2011-02-15 | 2012-02-14 | Humanized m-csf mice |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015214219A Division JP6188765B2 (ja) | 2011-02-15 | 2015-10-30 | ヒト化ｍ−ｃｓｆマウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510520A JP2014510520A (ja) | 2014-05-01 |
| JP2014510520A5 true JP2014510520A5 (enExample) | 2015-04-02 |
| JP5834097B2 JP5834097B2 (ja) | 2015-12-16 |
Family
ID=46673120
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554547A Active JP5834097B2 (ja) | 2011-02-15 | 2012-02-14 | ヒト化ｍ−ｃｓｆマウス |
| JP2015214219A Active JP6188765B2 (ja) | 2011-02-15 | 2015-10-30 | ヒト化ｍ−ｃｓｆマウス |
| JP2017148922A Active JP6505786B2 (ja) | 2011-02-15 | 2017-08-01 | ヒト化ｍ−ｃｓｆマウス |
| JP2019059688A Active JP6732987B2 (ja) | 2011-02-15 | 2019-03-27 | ヒト化ｍ−ｃｓｆマウス |
| JP2020117479A Active JP7181911B2 (ja) | 2011-02-15 | 2020-07-08 | ヒト化ｍ－ｃｓｆマウス |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015214219A Active JP6188765B2 (ja) | 2011-02-15 | 2015-10-30 | ヒト化ｍ−ｃｓｆマウス |
| JP2017148922A Active JP6505786B2 (ja) | 2011-02-15 | 2017-08-01 | ヒト化ｍ−ｃｓｆマウス |
| JP2019059688A Active JP6732987B2 (ja) | 2011-02-15 | 2019-03-27 | ヒト化ｍ−ｃｓｆマウス |
| JP2020117479A Active JP7181911B2 (ja) | 2011-02-15 | 2020-07-08 | ヒト化ｍ－ｃｓｆマウス |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US8847004B2 (enExample) |
| EP (3) | EP2675271B1 (enExample) |
| JP (5) | JP5834097B2 (enExample) |
| KR (6) | KR102585058B1 (enExample) |
| CN (3) | CN105861553B (enExample) |
| AU (1) | AU2012217836B2 (enExample) |
| CA (1) | CA2826714C (enExample) |
| DK (3) | DK4233537T3 (enExample) |
| ES (3) | ES3040596T3 (enExample) |
| FI (2) | FI4233537T3 (enExample) |
| IL (7) | IL227704A0 (enExample) |
| MX (3) | MX338971B (enExample) |
| MY (1) | MY162984A (enExample) |
| PT (3) | PT2675271T (enExample) |
| RU (2) | RU2577978C2 (enExample) |
| SG (3) | SG192606A1 (enExample) |
| WO (1) | WO2012112544A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011002988A1 (en) | 2009-07-01 | 2011-01-06 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for severe combined immunodeficiency (scid) |
| EP3417701B1 (en) | 2009-10-06 | 2021-12-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| RU2577978C2 (ru) | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
| RU2751240C2 (ru) | 2011-10-28 | 2021-07-12 | Регенерон Фармасьютикалс, Инк. | Гуманизированные il-6 и рецептор il-6 |
| US8962913B2 (en) | 2012-06-18 | 2015-02-24 | Regeneron Pharmaceuticals, Inc. | Humanized IL-7 rodents |
| NZ746089A (en) | 2012-09-07 | 2020-05-29 | Institute For Res In Biomedicine Irb | Genetically modified non-human animals and methods of use thereof |
| ES2748662T3 (es) | 2012-11-05 | 2020-03-17 | Institute For Res In Biomedicine Irb | Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos |
| JP6475172B2 (ja) | 2013-02-20 | 2019-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ラットの遺伝子組換え |
| CN103409468B (zh) * | 2013-03-20 | 2015-08-12 | 中国科学院广州生物医药与健康研究院 | 一种免疫缺陷小鼠模型的建立方法 |
| EP3456831B1 (en) | 2013-04-16 | 2021-07-14 | Regeneron Pharmaceuticals, Inc. | Targeted modification of rat genome |
| EP3461811A1 (en) | 2013-06-17 | 2019-04-03 | 3M Innovative Properties Co. | Process for preparing guanidino-functional monomers |
| SMT202500280T1 (it) | 2013-09-23 | 2025-09-12 | Regeneron Pharma | Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| EP3071024B1 (en) * | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| EP3430898A1 (en) * | 2013-11-19 | 2019-01-23 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized a proliferation-inducing ligand gene |
| US9795121B2 (en) | 2014-05-05 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Humanized C3 animals |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| KR102821645B1 (ko) | 2014-05-19 | 2025-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
| BR112016026245A2 (pt) * | 2014-05-30 | 2018-02-20 | Regeneron Pharma | ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor? |
| ES2969389T3 (es) | 2014-12-05 | 2024-05-17 | Regeneron Pharma | Animales no humanos que tienen un gen del grupo de diferenciación 47 humanizado |
| EP4399969A3 (en) * | 2014-12-09 | 2024-10-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized cluster of differentiation 274 gene |
| SG10202103445QA (en) | 2015-04-13 | 2021-05-28 | Regeneron Pharma | Humanized sirpa-il15 knockin mice and methods of use thereof |
| CN105994125B (zh) * | 2015-04-15 | 2019-05-17 | 中国科学院广州生物医药与健康研究院 | 一种评价免疫缺陷小鼠模型的免疫缺陷程度的方法 |
| US20180289840A1 (en) * | 2015-05-24 | 2018-10-11 | Central Institute For Experimental Animals | Method for Evaluating Hematological Toxicity of Drug Under Evaluation, and Model for Evaluating Hematological Toxicity of Drug Under Evaluation |
| TWI810145B (zh) | 2015-06-23 | 2023-08-01 | 杰克森實驗室 | 具有病患衍生之異種移植物之非ｈｌａ配對的人源化ｎｓｇ小鼠模式 |
| CN105145486A (zh) * | 2015-07-22 | 2015-12-16 | 中国医学科学院医学实验动物研究所 | Rag2基因敲除大鼠在建立个性化肿瘤治疗模型中的应用 |
| PT3376857T (pt) | 2015-11-20 | 2021-05-27 | Regeneron Pharma | Animais não humanos com um gene humanizado 3 de ativação de linfócitos |
| US10582702B2 (en) | 2016-02-04 | 2020-03-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered ANGPTL8 gene |
| KR101887051B1 (ko) * | 2016-02-12 | 2018-08-10 | 한국과학기술원 | 오브젝트 탐닉행동을 활용한 동물행동 조절 방법 |
| CA3014645C (en) | 2016-02-29 | 2022-10-25 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized tmprss gene |
| JP7458185B2 (ja) | 2016-11-30 | 2024-03-29 | ザ ジャクソン ラボラトリー | 改善されたヒト自然免疫細胞の発生を有するヒト化マウスモデル |
| EP4361637A3 (en) | 2017-04-17 | 2024-07-17 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug for use in humans |
| EP3585162B1 (en) | 2017-09-29 | 2023-08-30 | Regeneron Pharmaceuticals, Inc. | Rodents comprising a humanized ttr locus and methods of use |
| HUE067361T2 (hu) | 2018-07-16 | 2024-10-28 | Regeneron Pharma | Ditra betegség rágcsáló modelljei és alkalmazásaik |
| WO2020041174A1 (en) * | 2018-08-20 | 2020-02-27 | The Jackson Laboratory | Method of determining toxicity of an immunomodulatory drug |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN111073907B (zh) * | 2018-12-25 | 2025-07-29 | 百奥赛图江苏基因生物技术有限公司 | 人源化细胞因子csf1基因改造非人动物的构建方法及应用 |
| AU2020253532B2 (en) | 2019-04-04 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized coagulation factor 12 locus |
| WO2020247452A1 (en) | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
| SG11202111256XA (en) | 2019-06-07 | 2021-11-29 | Regeneron Pharma | Non-human animals comprising a humanized albumin locus |
| WO2021011853A2 (en) * | 2019-07-17 | 2021-01-21 | Yale University | Genetically modified non-human animals and methods of use thereof |
| CN114829882B (zh) | 2019-11-05 | 2023-02-28 | 阿比尔技术公司 | 植物产品中感染的预测 |
| JP2023511626A (ja) * | 2020-01-28 | 2023-03-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化ｐｎｐｌａ３遺伝子座を含む非ヒト動物および使用方法 |
| JP2023542539A (ja) | 2020-09-24 | 2023-10-10 | ザ ジャクソン ラボラトリー | 免疫細胞療法を評価するためのヒト化マウスモデル |
| CN113100175B (zh) * | 2021-03-08 | 2022-07-12 | 北京大学人民医院 | 一种巨细胞病毒感染的人源化小鼠模型及其构建方法 |
| CN114853871B (zh) * | 2021-04-20 | 2024-04-05 | 百奥赛图(北京)医药科技股份有限公司 | Csf1和/或csf1r基因人源化的非人动物及其构建方法和应用 |
| WO2024020057A1 (en) | 2022-07-19 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified animal model and its use to model the human immune system |
| US20250255282A1 (en) | 2024-02-08 | 2025-08-14 | Regeneron Pharmaceuticals, Inc. | Vectors, genetically modified cells, and genetically modified non-human animals comprising the same |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US5573930A (en) * | 1985-02-05 | 1996-11-12 | Cetus Oncology Corporation | DNA encoding various forms of colony stimulating factor-1 |
| HU215241B (hu) | 1986-10-24 | 1998-11-30 | Cetus Corp. | Eljárás telepstimuláló faktor-1 új formáinak előállítására, valamint az eljárásban alkalmazható expressziós kazetta, vektor és rekombináns gazdasejtek előállítására |
| ES2071620T3 (es) | 1987-12-23 | 1995-07-01 | Univ Leland Stanford Junior | Mamiferos inmunodeficientes quimericos y su utilizacion. |
| JP2981486B2 (ja) | 1988-06-14 | 1999-11-22 | メディカル・バイオロジー・インスティチュート | 哺乳動物の免疫系研究方法 |
| US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
| DE69131331T2 (de) | 1990-01-15 | 2000-03-02 | Yeda Research And Development Co., Ltd. | Dauerhafte Verpflanzung und Entwicklung menschlicher hämatopoietischer Zellinien bei normalen Säugetieren |
| US5652373A (en) | 1990-01-15 | 1997-07-29 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| DK0481058T3 (da) | 1990-05-03 | 1996-12-02 | Systemix Inc | Humant, lymfatisk væv i en immunokompromitteret vært |
| US5633426A (en) | 1990-05-25 | 1997-05-27 | Systemix, Inc. | In vivo use of human bone marrow for investigation and production |
| JPH05500617A (ja) | 1990-05-25 | 1993-02-12 | システミックス，インコーポレイティド | 免疫処理された宿主におけるヒト末梢血液細胞 |
| CA2103705C (en) | 1991-02-11 | 1996-01-30 | Ayub K. Ommaya | Spinal fluid driven artificial organ |
| US5222982A (en) | 1991-02-11 | 1993-06-29 | Ommaya Ayub K | Spinal fluid driven artificial organ |
| EP0517199A1 (en) | 1991-06-04 | 1992-12-09 | Yeda Research And Development Company, Ltd. | Durable engraftment of human tissue and cells in normal mammals |
| WO1993005796A1 (en) | 1991-09-19 | 1993-04-01 | The Scripps Research Institute | Method for producing human antibodies in a non-human animal, and animals therefor |
| EP0539970B1 (en) | 1991-10-30 | 1999-05-26 | Idemitsu Kosan Company Limited | Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby |
| US6353150B1 (en) | 1991-11-22 | 2002-03-05 | Hsc Research And Development Limited Partnership | Chimeric mammals with human hematopoietic cells |
| WO1993018144A1 (en) | 1992-03-05 | 1993-09-16 | The Trustees Of Columbia University Of The City Of New York | Recombination activating gene deficient animal |
| US5866757A (en) | 1992-06-02 | 1999-02-02 | Yeda Research And Development Co. Ltd. | Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems |
| US6018096A (en) | 1993-05-03 | 2000-01-25 | Surrogen, Inc. | Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells |
| CA2103693A1 (en) | 1993-08-06 | 1995-02-07 | Steven Gallinger | Animal model of the human immune system |
| WO1996003495A1 (en) | 1994-07-27 | 1996-02-08 | Merck & Co., Inc. | Bradykinin b2 receptor modified transgenic non-human animals |
| US6455756B1 (en) | 1994-08-12 | 2002-09-24 | Novartis Ag | Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice |
| US7273753B2 (en) * | 1996-08-02 | 2007-09-25 | Center Of Blood Research | Purification and uses of dendritic cells and monocytes |
| US6248721B1 (en) | 1997-04-09 | 2001-06-19 | Lung-Ji Chang | Method of using mouse model for evaluation of HIV vaccines |
| EP0973381B1 (en) | 1997-04-09 | 2010-03-03 | AMDL, Inc. | Animal model for evaluation of vaccines |
| US20030028911A1 (en) | 1999-08-31 | 2003-02-06 | Manley Huang | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| CA2382383A1 (en) * | 1999-08-31 | 2001-03-08 | Genencor International, Inc. | Transgenic mammal capable of facilitating production of donor-specific functional immunity |
| JP2004500810A (ja) | 1999-12-09 | 2004-01-15 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | Ｉｌ−６様ポリヌクレオチド、ポリペプチド、および抗体 |
| WO2002022786A1 (en) | 2000-09-14 | 2002-03-21 | Genetrol Biotherapeutics, Inc. | Method and cell composition for screening compounds for anti-inflammatory activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2002363322A1 (en) | 2001-10-26 | 2003-05-19 | Large Scale Biology Corporation | Endothelial cell derived hemotopoietic growth factor |
| JP4087338B2 (ja) | 2001-11-15 | 2008-05-21 | キリンファーマ株式会社 | キメラ非ヒト動物 |
| JPWO2004005496A1 (ja) | 2002-07-05 | 2005-11-04 | 麒麟麦酒株式会社 | 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団 |
| CN101250553A (zh) | 2002-07-13 | 2008-08-27 | 上海医学遗传研究所 | 一种促人血小板生成素表达载体及其构建方法 |
| AU2003278790A1 (en) | 2002-09-09 | 2004-03-29 | California Institute Of Technology | Methods and compositions for the generation of humanized mice |
| EP1418185A1 (en) * | 2002-11-11 | 2004-05-12 | Aventis Pharma Deutschland GmbH | Use of EDG2 receptor in an animal model of heart failure |
| EP1573314B1 (en) | 2002-12-16 | 2008-07-23 | Genentech, Inc. | Transgenic mice expressing human cd20 |
| CN1751236A (zh) * | 2002-12-16 | 2006-03-22 | 健泰科生物技术公司 | 表达人cd20的转基因小鼠 |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| US7759541B2 (en) | 2004-12-13 | 2010-07-20 | Iti Life Sciences | Transgenic animals for assessing drug metabolism and toxicity |
| GB2434578A (en) | 2006-01-26 | 2007-08-01 | Univ Basel | Transgenic animals |
| SI2019683T2 (sl) | 2006-04-25 | 2022-10-28 | The Regents Of The University Of California | Dajanje rastnih faktorjev za zdravljenje motenj CŽS |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| WO2008060360A2 (en) | 2006-09-28 | 2008-05-22 | Surmodics, Inc. | Implantable medical device with apertures for delivery of bioactive agents |
| WO2008069659A1 (en) | 2006-12-05 | 2008-06-12 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Improved xenogenic immune system in a non-human mammal |
| CA2687688C (en) * | 2007-05-23 | 2017-03-28 | Sangamo Biosciences, Inc. | Methods and compositions for increased transgene expression in t cells |
| GB0718029D0 (en) * | 2007-09-14 | 2007-10-24 | Iti Scotland Ltd | Two step cluster deletion and humanisation |
| US20110118446A1 (en) | 2007-09-28 | 2011-05-19 | The General Hospital Corporation | Methods and compositions for antibody production |
| EP2257250A2 (en) | 2008-01-29 | 2010-12-08 | Gilbert H. Kliman | Drug delivery devices, kits and methods therefor |
| AU2013204613A1 (en) | 2008-12-24 | 2013-05-16 | The Kingdom of The Netherlands, Represented by The Minister of Health, Welfare and Sport | Modified Streptococcus pneumonia pneumolysin (PLY) polypeptides |
| CN102725400A (zh) | 2009-06-29 | 2012-10-10 | 麻省理工学院 | 制造人源化的非人类哺乳动物的方法 |
| JP2012531894A (ja) | 2009-06-29 | 2012-12-13 | レスコフ，イリヤ，ビー． | ヒト血液癌の非ヒト哺乳動物モデル |
| RU2425880C2 (ru) | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| EP3417701B1 (en) | 2009-10-06 | 2021-12-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice and engraftment |
| EP2618656B1 (en) | 2010-09-20 | 2018-06-20 | Yale University, Inc. | HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE |
| WO2012051572A1 (en) | 2010-10-15 | 2012-04-19 | Massachusetts Institute Of Technology | A humanized non-human mammal model of malaria and uses thereof |
| RU2577978C2 (ru) | 2011-02-15 | 2016-03-20 | Ридженерон Фармасьютикалз, Инк. | Гуманизированные m-csf мыши |
| RU2751240C2 (ru) | 2011-10-28 | 2021-07-12 | Регенерон Фармасьютикалс, Инк. | Гуманизированные il-6 и рецептор il-6 |
| NZ746089A (en) | 2012-09-07 | 2020-05-29 | Institute For Res In Biomedicine Irb | Genetically modified non-human animals and methods of use thereof |
| ES2748662T3 (es) | 2012-11-05 | 2020-03-17 | Institute For Res In Biomedicine Irb | Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos |
| SMT202500280T1 (it) | 2013-09-23 | 2025-09-12 | Regeneron Pharma | Animali non umani aventi un gene umanizzato della proteina regolatrice del segnale |
| TR201904342T4 (tr) | 2013-10-15 | 2019-05-21 | Regeneron Pharma | Hümani̇ze il-15 hayvanlar |
| KR102821645B1 (ko) | 2014-05-19 | 2025-06-19 | 리제너론 파마슈티칼스 인코포레이티드 | 인간 epo를 발현하는 유전자 변형된 비-인간 동물 |
| SG10202103445QA (en) | 2015-04-13 | 2021-05-28 | Regeneron Pharma | Humanized sirpa-il15 knockin mice and methods of use thereof |
| AU2017290710A1 (en) | 2016-06-29 | 2019-01-24 | Menlo Therapeutics Inc. | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions |
-
2012
- 2012-02-14 RU RU2013142043/10A patent/RU2577978C2/ru active
- 2012-02-14 EP EP12746594.6A patent/EP2675271B1/en active Active
- 2012-02-14 CN CN201610297251.XA patent/CN105861553B/zh active Active
- 2012-02-14 FI FIEP23161285.4T patent/FI4233537T3/fi active
- 2012-02-14 KR KR1020227013434A patent/KR102585058B1/ko active Active
- 2012-02-14 US US13/372,787 patent/US8847004B2/en active Active
- 2012-02-14 WO PCT/US2012/025040 patent/WO2012112544A2/en not_active Ceased
- 2012-02-14 SG SG2013059076A patent/SG192606A1/en unknown
- 2012-02-14 CN CN201280018139.8A patent/CN103547148B/zh active Active
- 2012-02-14 MX MX2013009406A patent/MX338971B/es active IP Right Grant
- 2012-02-14 SG SG10202008003VA patent/SG10202008003VA/en unknown
- 2012-02-14 ES ES23161285T patent/ES3040596T3/es active Active
- 2012-02-14 SG SG10201601067WA patent/SG10201601067WA/en unknown
- 2012-02-14 FI FIEP18166409.5T patent/FI3375284T3/fi active
- 2012-02-14 KR KR1020217015137A patent/KR102390850B1/ko active Active
- 2012-02-14 MX MX2017011324A patent/MX380588B/es unknown
- 2012-02-14 DK DK23161285.4T patent/DK4233537T3/da active
- 2012-02-14 EP EP18166409.5A patent/EP3375284B1/en active Active
- 2012-02-14 KR KR1020237033247A patent/KR102714361B1/ko active Active
- 2012-02-14 ES ES12746594.6T patent/ES2685790T3/es active Active
- 2012-02-14 KR KR1020197038167A patent/KR102109172B1/ko active Active
- 2012-02-14 JP JP2013554547A patent/JP5834097B2/ja active Active
- 2012-02-14 KR KR1020207012878A patent/KR102256316B1/ko active Active
- 2012-02-14 CN CN202010697865.3A patent/CN111808879B/zh active Active
- 2012-02-14 ES ES18166409T patent/ES2948210T3/es active Active
- 2012-02-14 DK DK18166409.5T patent/DK3375284T3/da active
- 2012-02-14 CA CA2826714A patent/CA2826714C/en active Active
- 2012-02-14 AU AU2012217836A patent/AU2012217836B2/en active Active
- 2012-02-14 DK DK12746594.6T patent/DK2675271T3/en active
- 2012-02-14 PT PT12746594T patent/PT2675271T/pt unknown
- 2012-02-14 RU RU2016104468A patent/RU2730643C2/ru active
- 2012-02-14 EP EP23161285.4A patent/EP4233537B1/en active Active
- 2012-02-14 PT PT181664095T patent/PT3375284T/pt unknown
- 2012-02-14 PT PT231612854T patent/PT4233537T/pt unknown
- 2012-02-14 MY MYPI2013002891A patent/MY162984A/en unknown
- 2012-02-14 MX MX2016001791A patent/MX350385B/es unknown
- 2012-02-14 KR KR1020137020995A patent/KR102061143B1/ko active Active
-
2013
- 2013-07-29 IL IL227704A patent/IL227704A0/en active IP Right Grant
-
2014
- 2014-08-26 US US14/469,308 patent/US9655352B2/en active Active
-
2015
- 2015-05-13 IL IL238781A patent/IL238781A/en active IP Right Grant
- 2015-06-11 IL IL239350A patent/IL239350A/en active IP Right Grant
- 2015-10-30 JP JP2015214219A patent/JP6188765B2/ja active Active
-
2017
- 2017-04-14 US US15/488,177 patent/US10785966B2/en active Active
- 2017-07-31 IL IL253743A patent/IL253743B/en active IP Right Grant
- 2017-08-01 JP JP2017148922A patent/JP6505786B2/ja active Active
-
2019
- 2019-03-27 JP JP2019059688A patent/JP6732987B2/ja active Active
- 2019-05-26 IL IL266886A patent/IL266886B/en active IP Right Grant
-
2020
- 2020-07-08 JP JP2020117479A patent/JP7181911B2/ja active Active
- 2020-08-21 US US17/000,105 patent/US12127536B2/en active Active
- 2020-10-29 IL IL278385A patent/IL278385B/en unknown
-
2021
- 2021-11-16 IL IL288167A patent/IL288167A/en unknown
-
2024
- 2024-09-24 US US18/895,171 patent/US20250072406A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510520A5 (enExample) | ||
| Aegerter et al. | Biology of lung macrophages in health and disease | |
| Garrett et al. | Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system | |
| RU2013142043A (ru) | Гуманизированные m-csf мыши | |
| Castellanos et al. | Microbiota-induced TNF-like ligand 1A drives group 3 innate lymphoid cell-mediated barrier protection and intestinal T cell activation during colitis | |
| Scott et al. | The transcription factor ZEB2 is required to maintain the tissue-specific identities of macrophages | |
| Magis et al. | High-level correction of the sickle mutation is amplified in vivo during erythroid differentiation | |
| Ebbo et al. | Innate lymphoid cells: major players in inflammatory diseases | |
| Tesi et al. | Hemophagocytic lymphohistiocytosis in 2 patients with underlying IFN-γ receptor deficiency | |
| Haas et al. | Development of interleukin-17-producing γδ T cells is restricted to a functional embryonic wave | |
| van de Laar et al. | Yolk sac macrophages, fetal liver, and adult monocytes can colonize an empty niche and develop into functional tissue-resident macrophages | |
| Tian et al. | Targeting IL-10 in auto-immune diseases | |
| Kotyla et al. | Clinical aspects of Janus Kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis | |
| Dolfi et al. | Unravelling the sex-specific diversity and functions of adrenal gland macrophages | |
| Sagiv et al. | p53 in bronchial club cells facilitates chronic lung inflammation by promoting senescence | |
| Dodard et al. | Inflammation-induced lactate leads to rapid loss of hepatic tissue-resident NK cells | |
| Tran et al. | Delicate balances in cancer chemotherapy: modeling immune recruitment and emergence of systemic drug resistance | |
| Pohjoismäki et al. | Overexpression of Twinkle-helicase protects cardiomyocytes from genotoxic stress caused by reactive oxygen species | |
| Márquez et al. | Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis | |
| Sato et al. | Production of IL-17A at innate immune phase leads to decreased Th1 immune response and attenuated host defense against infection with Cryptococcus deneoformans | |
| Kim et al. | Repeated LPS induces training and tolerance of microglial responses across brain regions | |
| Swafford et al. | Canonical Wnt signaling in CD11c+ APCs regulates microbiota-induced inflammation and immune cell homeostasis in the colon | |
| Khan et al. | Beyond the complement cascade: insights into systemic immunosenescence and inflammaging in age-related macular degeneration and current barriers to treatment | |
| Alexander et al. | A diet-dependent host metabolite shapes the gut microbiota to protect from autoimmunity | |
| Kaur et al. | The potential role of cytotoxic immune effectors in induction, progression and pathogenesis of amyotrophic lateral sclerosis (ALS) |